483
Gland Pharma Limited, Units I+II Pashamylaram SiteFDA 483 - Gland Pharma Limited, Units I+II Pashamylaram Site - November 07, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Gland Pharma Limited, a parenteral drug manufacturer in Patancheru, India, revealed significant deficiencies across multiple areas. Observations included inadequate investigations into discrepancies and foreign materials, insufficient microbial control measures, and failures in laboratory controls for product quality and validation. Additionally, the firm was cited for not taking representative samples of components for testing.
- Inspection Date
- November 7, 2019
- Product Type
- Drugs
Open in Dashboard
ID · 767d64c6-92ff-4f24-8fde-19bd74da6cdc